Free Trial

Myriad Genetics (MYGN) Financials

Myriad Genetics logo
$4.15 +0.24 (+6.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.16 +0.00 (+0.12%)
As of 05/27/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Myriad Genetics

Annual Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-127 -263 -112
Consolidated Net Income / (Loss)
-127 -263 -112
Net Income / (Loss) Continuing Operations
-127 -263 -112
Total Pre-Tax Income
-124 -262 -141
Total Operating Income
-124 -257 -141
Total Gross Profit
585 517 476
Total Revenue
838 753 678
Operating Revenue
838 753 678
Total Cost of Revenue
252 236 202
Operating Cost of Revenue
252 236 202
Total Operating Expenses
709 774 617
Selling, General & Admin Expense
276 284 248
Marketing Expense
284 289 267
Research & Development Expense
113 89 85
Other Operating Expenses / (Income)
-21 113 0.00
Impairment Charge
57 0.00 17
Total Other Income / (Expense), net
0.00 -4.80 0.00
Interest Expense
2.80 2.90 3.20
Interest & Investment Income
1.70 2.50 2.60
Other Income / (Expense), net
1.10 -4.40 0.60
Income Tax Expense
3.80 1.10 -29
Basic Earnings per Share
($1.41) ($3.18) ($1.39)
Weighted Average Basic Shares Outstanding
90.60M 82.80M 80.60M
Diluted Earnings per Share
($1.41) ($3.18) ($1.39)
Weighted Average Diluted Shares Outstanding
90.60M 82.80M 80.60M
Weighted Average Basic & Diluted Shares Outstanding
91.31M 89.87M 81.22M

Quarterly Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-43 -22 -37 -26 -31 -61 -116 -55 -42 -35
Consolidated Net Income / (Loss)
-43 -22 -37 -26 -31 -61 -116 -55 -42 -35
Net Income / (Loss) Continuing Operations
-43 -22 -37 -26 -31 -61 -116 -55 -42 -35
Total Pre-Tax Income
-39 -21 -37 -26 -32 -61 -116 -53 -52 -44
Total Operating Income
-39 -20 -37 -28 -31 -60 -114 -52 -52 -45
Total Gross Profit
151 150 147 138 135 134 126 122 124 106
Total Revenue
211 213 212 202 197 192 184 181 178 156
Operating Revenue
211 213 212 202 197 192 184 181 178 156
Total Cost of Revenue
60 64 64 65 62 58 58 59 54 50
Operating Cost of Revenue
60 64 64 65 62 58 58 59 54 50
Total Operating Expenses
190 170 184 166 166 194 239 174 176 151
Selling, General & Admin Expense
-149 139 145 141 -145 136 141 152 -120 131
Research & Development Expense
33 29 27 25 21 24 21 23 23 21
Total Other Income / (Expense), net
-0.10 -1.20 -0.70 2.00 -0.90 -1.10 -2.40 -0.40 0.10 0.80
Interest Expense
0.70 0.80 0.80 0.50 0.90 1.00 0.50 0.50 0.90 0.80
Interest & Investment Income
0.30 0.40 0.40 0.60 0.70 0.60 0.50 0.70 1.00 1.10
Other Income / (Expense), net
0.30 -0.80 -0.30 1.90 -0.70 -0.70 -2.40 -0.60 - 0.50
Income Tax Expense
3.30 0.90 -0.50 0.10 -1.10 0.10 0.00 2.10 -9.80 -9.10
Basic Earnings per Share
($0.47) ($0.24) ($0.41) ($0.29) ($0.34) ($0.75) ($1.42) ($0.67) ($0.52) ($0.43)
Weighted Average Basic Shares Outstanding
90.60M 90.90M 90.60M 89.90M 82.80M 81.90M 81.70M 81.30M 80.60M 80.70M
Diluted Earnings per Share
($0.47) ($0.24) ($0.41) ($0.29) ($0.34) ($0.75) ($1.42) ($0.67) ($0.52) ($0.43)
Weighted Average Diluted Shares Outstanding
90.60M 90.90M 90.60M 89.90M 82.80M 81.90M 81.70M 81.30M 80.60M 80.70M
Weighted Average Basic & Diluted Shares Outstanding
91.31M 91.04M 90.82M 90.51M 89.87M 82.20M 81.88M 81.56M 81.22M 81.03M

Annual Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-29 75 -192
Net Cash From Operating Activities
-8.70 -111 -106
Net Cash From Continuing Operating Activities
-8.70 -111 -106
Net Income / (Loss) Continuing Operations
-127 -263 -112
Consolidated Net Income / (Loss)
-127 -263 -112
Depreciation Expense
61 62 53
Non-Cash Adjustments To Reconcile Net Income
111 65 85
Changes in Operating Assets and Liabilities, net
-53 14 -132
Net Cash From Investing Activities
-12 32 -78
Net Cash From Continuing Investing Activities
-12 32 -78
Purchase of Property, Plant & Equipment
-30 -73 -45
Acquisitions
0.00 0.00 -57
Purchase of Investments
0.00 0.00 -103
Divestitures
8.80 0.00 0.00
Sale and/or Maturity of Investments
9.00 105 128
Net Cash From Financing Activities
-7.40 153 -8.00
Net Cash From Continuing Financing Activities
-7.40 153 -8.00
Repayment of Debt
-120 -42 -0.70
Issuance of Debt
120 80 0.00
Issuance of Common Equity
5.90 124 6.30
Other Financing Activities, net
-14 -9.00 -14
Effect of Exchange Rate Changes
-1.00 0.60 -0.60

Quarterly Cash Flow Statements for Myriad Genetics

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
2.10 8.60 -4.40 -35 56 -28 50 -3.30 -44 4.50
Net Cash From Operating Activities
6.60 0.70 2.60 -19 -55 -22 -0.90 -33 -7.30 -2.80
Net Cash From Continuing Operating Activities
6.60 0.70 2.60 -19 -55 -22 -0.90 -33 -7.30 -2.80
Net Income / (Loss) Continuing Operations
-43 -22 -37 -26 -31 -61 -116 -55 -42 -35
Consolidated Net Income / (Loss)
-43 -22 -37 -26 -31 -61 -116 -55 -42 -35
Depreciation Expense
15 16 15 16 15 14 13 19 14 13
Non-Cash Adjustments To Reconcile Net Income
58 15 28 10 8.00 15 19 24 27 21
Changes in Operating Assets and Liabilities, net
-23 -8.20 -3.30 -19 -58 11 83 -22 -5.60 -1.70
Net Cash From Investing Activities
-5.90 7.50 -6.40 -7.10 -12 -2.50 12 35 -36 11
Net Cash From Continuing Investing Activities
-5.90 7.50 -6.40 -7.10 -12 -2.50 12 35 -36 11
Purchase of Property, Plant & Equipment
-5.90 -6.30 -8.90 -8.60 -14 -18 -19 -24 -15 -18
Net Cash From Financing Activities
2.10 -3.10 2.40 -8.80 122 -2.50 38 -4.90 -2.10 -3.60
Net Cash From Continuing Financing Activities
2.10 -3.10 2.40 -8.80 122 -2.50 38 -4.90 -2.10 -3.60
Repayment of Debt
-20 -20 -20 -60 -40 -0.20 -1.40 0.00 - -0.70
Issuance of Debt
20 20 20 60 40 - 40 0.00 - -
Issuance of Common Equity
2.90 - - - 124 - - - 2.40 0.90
Other Financing Activities, net
-1.30 -3.10 -0.60 -8.80 -1.60 -2.30 -0.20 -4.90 -4.50 -3.80
Effect of Exchange Rate Changes
-0.70 1.20 -0.70 -0.80 0.70 -0.60 0.30 0.20 0.70 -0.50

Annual Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
1,028 1,147 1,199
Total Current Assets
298 314 275
Cash & Equivalents
102 132 57
Short-Term Investments
0.00 8.80 58
Accounts Receivable
121 114 102
Inventories, net
28 22 20
Prepaid Expenses
31 19 20
Current Deferred & Refundable Income Taxes
16 17 18
Plant, Property, & Equipment, net
117 119 83
Total Noncurrent Assets
612 714 841
Goodwill
286 287 287
Intangible Assets
262 350 380
Other Noncurrent Operating Assets
64 77 119
Total Liabilities & Shareholders' Equity
1,028 1,147 1,199
Total Liabilities
327 363 313
Total Current Liabilities
164 156 137
Accounts Payable
32 26 29
Accrued Expenses
119 114 94
Other Current Liabilities
13 16 14
Total Noncurrent Liabilities
162 207 176
Long-Term Debt
40 39 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
33 30 27
Other Noncurrent Operating Liabilities
90 139 149
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
701 783 886
Total Preferred & Common Equity
701 783 886
Total Common Equity
701 783 886
Common Stock
1,459 1,416 1,261
Retained Earnings
-757 -630 -366
Accumulated Other Comprehensive Income / (Loss)
-0.80 -3.70 -8.90

Quarterly Balance Sheets for Myriad Genetics

This table presents Myriad Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
1,081 1,085 1,111 1,149 1,187 1,169 1,212
Total Current Assets
293 292 290 265 294 262 352
Cash & Equivalents
100 92 97 76 103 54 111
Short-Term Investments
0.00 4.90 7.40 10 19 25 83
Accounts Receivable
126 118 118 115 112 119 102
Inventories, net
26 26 25 25 23 22 20
Prepaid Expenses
24 22 25 21 21 24 20
Current Deferred & Refundable Income Taxes
17 18 18 18 18 18 18
Plant, Property, & Equipment, net
115 116 119 121 112 96 68
Total Noncurrent Assets
673 677 702 763 781 811 792
Goodwill
286 286 287 287 287 287 237
Intangible Assets
313 320 341 357 359 369 371
Other Noncurrent Operating Assets
74 71 74 120 129 125 119
Total Liabilities & Shareholders' Equity
1,081 1,085 1,111 1,149 1,187 1,169 1,212
Total Liabilities
350 345 351 466 452 334 295
Total Current Liabilities
154 149 146 209 221 143 129
Accounts Payable
30 33 33 34 40 37 30
Accrued Expenses
111 98 99 158 164 92 85
Other Current Liabilities
14 13 14 18 17 15 14
Total Noncurrent Liabilities
195 196 204 256 231 191 166
Long-Term Debt
39 39 39 39 38 - -
Noncurrent Deferred & Payable Income Tax Liabilities
31 31 31 32 33 33 38
Other Noncurrent Operating Liabilities
125 126 135 186 160 158 128
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
732 741 760 683 735 835 917
Total Preferred & Common Equity
732 741 760 683 735 835 917
Total Common Equity
732 741 760 683 735 835 917
Common Stock
1,446 1,437 1,420 1,287 1,278 1,264 1,252
Retained Earnings
-714 -692 -656 -598 -537 -421 -324
Accumulated Other Comprehensive Income / (Loss)
-0.10 -4.00 -4.20 -5.30 -5.40 -7.40 -11

Annual Metrics And Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
11.21% 11.03% -1.77%
EBITDA Growth
67.55% -116.04% -852.59%
EBIT Growth
53.25% -87.00% -173.44%
NOPAT Growth
52.02% -83.07% 26.19%
Net Income Growth
51.65% -135.09% -311.76%
EPS Growth
55.66% -128.78% -297.14%
Operating Cash Flow Growth
92.16% -4.33% -671.51%
Free Cash Flow Firm Growth
69.66% 40.75% -205.97%
Invested Capital Growth
-6.24% -4.93% 25.63%
Revenue Q/Q Growth
1.70% 2.56% 2.57%
EBITDA Q/Q Growth
-12.92% 14.81% -11.07%
EBIT Q/Q Growth
-5.79% 7.13% -6.95%
NOPAT Q/Q Growth
-6.65% 7.48% -6.92%
Net Income Q/Q Growth
-9.74% 4.05% -44.89%
EPS Q/Q Growth
-10.16% 5.36% -47.87%
Operating Cash Flow Q/Q Growth
87.57% -74.65% 2.03%
Free Cash Flow Firm Q/Q Growth
62.20% 16.23% -25.68%
Invested Capital Q/Q Growth
-4.85% 7.11% 8.93%
Profitability Metrics
- - -
Gross Margin
69.89% 68.64% 70.22%
EBITDA Margin
-7.31% -25.04% -12.87%
Operating Margin
-14.74% -34.17% -20.73%
EBIT Margin
-14.61% -34.76% -20.64%
Profit (Net Income) Margin
-15.20% -34.96% -16.51%
Tax Burden Percent
103.08% 100.42% 79.66%
Interest Burden Percent
100.90% 100.15% 100.43%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-13.11% -25.80% -15.31%
ROIC Less NNEP Spread (ROIC-NNEP)
36.35% 35.30% -10.52%
Return on Net Nonoperating Assets (RNNOA)
-4.05% -5.75% 3.22%
Return on Equity (ROE)
-17.15% -31.55% -12.08%
Cash Return on Invested Capital (CROIC)
-6.66% -20.74% -38.03%
Operating Return on Assets (OROA)
-11.26% -22.33% -11.11%
Return on Assets (ROA)
-11.71% -22.45% -8.89%
Return on Common Equity (ROCE)
-17.15% -31.55% -12.08%
Return on Equity Simple (ROE_SIMPLE)
-18.16% -33.62% -12.64%
Net Operating Profit after Tax (NOPAT)
-86 -180 -98
NOPAT Margin
-10.32% -23.92% -14.51%
Net Nonoperating Expense Percent (NNEP)
-49.46% -61.10% -4.79%
Return On Investment Capital (ROIC_SIMPLE)
-11.67% -21.93% -11.11%
Cost of Revenue to Revenue
30.11% 31.36% 29.78%
SG&A Expenses to Revenue
32.94% 37.67% 36.54%
R&D to Revenue
13.54% 11.78% 12.59%
Operating Expenses to Revenue
84.63% 102.81% 90.95%
Earnings before Interest and Taxes (EBIT)
-122 -262 -140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-61 -189 -87
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.78 2.01 1.33
Price to Tangible Book Value (P/TBV)
8.19 10.75 5.36
Price to Revenue (P/Rev)
1.49 2.09 1.73
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.86 2.16 1.41
Enterprise Value to Revenue (EV/Rev)
1.42 1.95 1.48
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.06 0.05 0.00
Long-Term Debt to Equity
0.06 0.05 0.00
Financial Leverage
-0.11 -0.16 -0.31
Leverage Ratio
1.46 1.41 1.36
Compound Leverage Factor
1.48 1.41 1.37
Debt to Total Capital
5.35% 4.69% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
5.35% 4.69% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
94.65% 95.31% 100.00%
Debt to EBITDA
-0.65 -0.20 0.00
Net Debt to EBITDA
1.03 0.54 0.00
Long-Term Debt to EBITDA
-0.65 -0.20 0.00
Debt to NOPAT
-0.46 -0.21 0.00
Net Debt to NOPAT
0.73 0.57 0.00
Long-Term Debt to NOPAT
-0.46 -0.21 0.00
Altman Z-Score
1.84 1.90 2.15
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
1.82 2.01 2.00
Quick Ratio
1.36 1.64 1.58
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-44 -145 -245
Operating Cash Flow to CapEx
-29.29% -151.30% -234.66%
Free Cash Flow to Firm to Interest Expense
-15.70 -49.96 -76.41
Operating Cash Flow to Interest Expense
-3.11 -38.24 -33.22
Operating Cash Flow Less CapEx to Interest Expense
-13.71 -63.52 -47.38
Efficiency Ratios
- - -
Asset Turnover
0.77 0.64 0.54
Accounts Receivable Turnover
7.11 6.98 7.03
Inventory Turnover
10.19 11.22 11.41
Fixed Asset Turnover
7.09 7.44 10.69
Accounts Payable Turnover
8.68 8.65 6.92
Days Sales Outstanding (DSO)
51.31 52.31 51.89
Days Inventory Outstanding (DIO)
35.82 32.53 31.98
Days Payable Outstanding (DPO)
42.04 42.19 52.76
Cash Conversion Cycle (CCC)
45.09 42.65 31.11
Capital & Investment Metrics
- - -
Invested Capital
638 681 716
Invested Capital Turnover
1.27 1.08 1.06
Increase / (Decrease) in Invested Capital
-43 -35 146
Enterprise Value (EV)
1,185 1,471 1,006
Market Capitalization
1,248 1,573 1,176
Book Value per Share
$7.70 $9.53 $10.93
Tangible Book Value per Share
$1.67 $1.78 $2.71
Total Capital
741 822 886
Total Debt
40 39 0.00
Total Long-Term Debt
40 39 0.00
Net Debt
-63 -102 -170
Capital Expenditures (CapEx)
30 73 45
Debt-free, Cash-free Net Working Capital (DFCFNWC)
32 17 23
Debt-free Net Working Capital (DFNWC)
134 158 137
Net Working Capital (NWC)
134 158 137
Net Nonoperating Expense (NNE)
41 83 14
Net Nonoperating Obligations (NNO)
-63 -102 -170
Total Depreciation and Amortization (D&A)
61 73 53
Debt-free, Cash-free Net Working Capital to Revenue
3.76% 2.23% 3.32%
Debt-free Net Working Capital to Revenue
15.99% 20.94% 20.25%
Net Working Capital to Revenue
15.99% 20.94% 20.25%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.41) ($3.18) ($1.39)
Adjusted Weighted Average Basic Shares Outstanding
90.60M 82.80M 80.60M
Adjusted Diluted Earnings per Share
($1.41) ($3.18) ($1.39)
Adjusted Weighted Average Diluted Shares Outstanding
90.60M 82.80M 80.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
91.31M 89.87M 81.22M
Normalized Net Operating Profit after Tax (NOPAT)
-47 -180 -87
Normalized NOPAT Margin
-5.57% -23.92% -12.76%
Pre Tax Income Margin
-14.74% -34.81% -20.73%
Debt Service Ratios
- - -
EBIT to Interest Expense
-43.71 -90.28 -43.75
NOPAT to Interest Expense
-30.88 -62.13 -30.76
EBIT Less CapEx to Interest Expense
-54.32 -115.55 -57.91
NOPAT Less CapEx to Interest Expense
-41.48 -87.41 -44.91
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Myriad Genetics

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
7.12% 11.15% 15.26% 11.59% 10.57% 22.70% 2.34% 9.88% 10.57% -6.52%
EBITDA Growth
-41.18% 88.87% 78.89% 69.16% 55.84% -48.73% -2,041.67% -165.08% -29.19% -157.19%
EBIT Growth
-20.87% 65.79% 68.30% 50.76% 38.51% -36.63% -555.93% -106.25% -21.11% -209.34%
NOPAT Growth
-24.52% 66.72% 67.90% 46.55% 39.85% -33.56% -538.76% -103.91% -21.11% 36.22%
Net Income Growth
-36.22% 63.95% 68.39% 52.47% 26.24% -74.64% -723.40% -166.83% -456.58% -242.68%
EPS Growth
-38.24% 68.00% 71.13% 56.72% 34.62% -74.42% -688.89% -157.69% -642.86% -243.33%
Operating Cash Flow Growth
112.07% 103.17% 388.89% 43.98% -649.32% -689.29% 98.19% 28.60% 23.16% 92.88%
Free Cash Flow Firm Growth
13.59% -142.72% 10.13% 108.02% 107.29% 84.87% 8.84% -171.45% -154.69% -136.52%
Invested Capital Growth
-6.24% 5.54% 4.61% -4.37% -4.93% -3.32% -2.71% 18.86% 25.63% 18.47%
Revenue Q/Q Growth
-1.27% 0.85% 4.60% 2.85% 2.45% 4.58% 1.27% 1.91% 13.68% -12.77%
EBITDA Q/Q Growth
-361.54% 76.04% -110.68% 39.41% 63.60% 54.57% -207.78% 13.25% -22.61% -554.17%
EBIT Q/Q Growth
-86.54% 43.48% -41.54% 19.00% 47.20% 47.63% -119.89% -1.15% -17.30% -151.41%
NOPAT Q/Q Growth
-95.50% 45.21% -30.82% 11.15% 47.75% 47.14% -117.82% 0.00% -16.00% -152.81%
Net Income Q/Q Growth
-92.31% 39.78% -41.15% 16.67% 49.10% 47.20% -112.25% -29.31% -20.51% -148.94%
EPS Q/Q Growth
-95.83% 41.46% -41.38% 14.71% 54.67% 47.18% -111.94% -28.85% -20.93% -138.89%
Operating Cash Flow Q/Q Growth
842.86% -73.08% 113.98% 66.00% -147.51% -2,355.56% 97.29% -354.79% -160.71% 94.37%
Free Cash Flow Firm Q/Q Growth
130.75% 11.11% -554.81% -8.63% 165.71% 67.09% 59.41% 16.92% -36.30% -98.34%
Invested Capital Q/Q Growth
-4.85% -0.71% -2.71% 2.00% 7.11% -1.58% -11.06% 1.40% 8.93% -0.96%
Profitability Metrics
- - - - - - - - - -
Gross Margin
71.65% 70.23% 69.55% 68.05% 68.67% 69.98% 68.50% 67.33% 69.69% 67.77%
EBITDA Margin
-11.40% -2.44% -10.26% -5.09% -8.65% -24.34% -56.02% -18.43% -21.65% -20.08%
Operating Margin
-18.57% -9.38% -17.26% -13.80% -15.97% -31.32% -61.96% -28.81% -29.36% -28.77%
EBIT Margin
-18.42% -9.75% -17.40% -12.86% -16.33% -31.68% -63.27% -29.14% -29.36% -28.45%
Profit (Net Income) Margin
-20.18% -10.36% -17.35% -12.86% -15.87% -31.94% -63.27% -30.19% -23.79% -22.44%
Tax Burden Percent
108.42% 104.25% 98.66% 100.39% 96.59% 100.16% 100.00% 103.99% 81.19% 79.41%
Interest Burden Percent
101.03% 101.92% 101.09% 99.62% 100.62% 100.66% 100.00% 99.62% 99.81% 99.33%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-16.50% -8.28% -14.67% -10.53% -12.06% -24.90% -46.29% -20.96% -21.68% -21.98%
ROIC Less NNEP Spread (ROIC-NNEP)
1.81% 6.63% -0.22% -3.12% -5.28% -12.38% -26.72% -12.85% -19.65% -20.91%
Return on Net Nonoperating Assets (RNNOA)
-0.20% -0.51% 0.02% 0.34% 0.86% 2.37% 5.92% 3.23% 6.02% 7.46%
Return on Equity (ROE)
-16.71% -8.78% -14.65% -10.19% -11.20% -22.53% -40.37% -17.73% -15.66% -14.51%
Cash Return on Invested Capital (CROIC)
-6.66% -17.80% -21.03% -18.51% -20.74% -26.75% -25.38% -34.74% -38.03% -32.10%
Operating Return on Assets (OROA)
-14.20% -7.20% -12.29% -8.73% -10.49% -19.71% -36.89% -16.70% -15.81% -14.77%
Return on Assets (ROA)
-15.55% -7.65% -12.25% -8.73% -10.19% -19.87% -36.89% -17.30% -12.81% -11.65%
Return on Common Equity (ROCE)
-16.71% -8.78% -14.65% -10.19% -11.20% -22.53% -40.37% -17.73% -15.66% -14.52%
Return on Equity Simple (ROE_SIMPLE)
0.00% -15.85% -20.96% -30.87% 0.00% -40.15% -33.76% -17.50% 0.00% -8.43%
Net Operating Profit after Tax (NOPAT)
-27 -14 -26 -20 -22 -42 -80 -37 -37 -32
NOPAT Margin
-13.00% -6.56% -12.08% -9.66% -11.18% -21.92% -43.37% -20.17% -20.55% -20.14%
Net Nonoperating Expense Percent (NNEP)
-18.32% -14.90% -14.45% -7.41% -6.78% -12.53% -19.58% -8.10% -2.03% -1.07%
Return On Investment Capital (ROIC_SIMPLE)
-3.70% -1.82% -3.28% -2.45% -2.67% -5.83% -10.29% -4.38% -4.13% -3.44%
Cost of Revenue to Revenue
28.35% 29.77% 30.45% 31.95% 31.33% 30.02% 31.50% 32.67% 30.32% 32.23%
SG&A Expenses to Revenue
-70.61% 65.21% 68.51% 69.54% -73.65% 70.92% 76.68% 83.72% -67.66% 83.44%
R&D to Revenue
15.62% 13.36% 12.81% 12.31% 10.68% 12.51% 11.55% 12.42% 13.16% 13.11%
Operating Expenses to Revenue
90.22% 79.61% 86.81% 81.85% 84.64% 101.30% 130.46% 96.14% 99.04% 96.55%
Earnings before Interest and Taxes (EBIT)
-39 -21 -37 -26 -32 -61 -116 -53 -52 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-24 -5.20 -22 -10 -17 -47 -103 -33 -39 -31
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.78 3.40 2.99 2.31 2.01 1.92 2.57 2.26 1.33 1.68
Price to Tangible Book Value (P/TBV)
8.19 18.72 16.44 13.27 10.75 32.67 21.19 10.56 5.36 4.97
Price to Revenue (P/Rev)
1.49 3.02 2.76 2.26 2.09 1.79 2.70 2.72 1.73 2.33
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.86 3.62 3.19 2.43 2.16 1.99 2.79 2.45 1.41 1.95
Enterprise Value to Revenue (EV/Rev)
1.42 2.95 2.69 2.18 1.95 1.72 2.58 2.56 1.48 1.93
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.06 0.05 0.05 0.05 0.05 0.06 0.05 0.00 0.00 0.00
Long-Term Debt to Equity
0.06 0.05 0.05 0.05 0.05 0.06 0.05 0.00 0.00 0.00
Financial Leverage
-0.11 -0.08 -0.10 -0.11 -0.16 -0.19 -0.22 -0.25 -0.31 -0.36
Leverage Ratio
1.46 1.58 1.54 1.43 1.41 1.48 1.42 1.36 1.36 1.35
Compound Leverage Factor
1.48 1.61 1.56 1.42 1.41 1.49 1.42 1.35 1.36 1.34
Debt to Total Capital
5.35% 5.06% 4.98% 4.85% 4.69% 5.33% 4.96% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
5.35% 5.06% 4.98% 4.85% 4.69% 5.33% 4.96% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
94.65% 94.94% 95.02% 95.15% 95.31% 94.67% 95.04% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.65 -0.72 -0.41 -0.22 -0.20 -0.17 -0.19 0.00 0.00 0.00
Net Debt to EBITDA
1.03 1.12 0.61 0.37 0.54 0.22 0.43 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.65 -0.72 -0.41 -0.22 -0.20 -0.17 -0.19 0.00 0.00 0.00
Debt to NOPAT
-0.46 -0.48 -0.36 -0.24 -0.21 -0.20 -0.21 0.00 0.00 0.00
Net Debt to NOPAT
0.73 0.75 0.54 0.40 0.57 0.25 0.49 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.46 -0.48 -0.36 -0.24 -0.21 -0.20 -0.21 0.00 0.00 0.00
Altman Z-Score
2.11 4.20 3.75 2.95 2.56 1.49 2.22 3.45 2.39 3.40
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.01%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.82 1.90 1.96 1.99 2.01 1.27 1.33 1.83 2.00 2.73
Quick Ratio
1.36 1.46 1.44 1.52 1.64 0.96 1.06 1.38 1.58 2.29
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
15 -49 -55 12 13 -20 -62 -152 -183 -134
Operating Cash Flow to CapEx
111.86% 11.11% 29.21% -216.28% -405.19% -126.29% -4.79% -141.28% -50.00% -15.82%
Free Cash Flow to Firm to Interest Expense
21.61 -61.50 -69.19 24.34 14.80 -20.27 -123.18 -303.48 -202.93 -167.50
Operating Cash Flow to Interest Expense
9.43 0.88 3.25 -37.20 -60.78 -22.10 -1.80 -66.40 -8.11 -3.50
Operating Cash Flow Less CapEx to Interest Expense
1.00 -7.00 -7.88 -54.40 -75.78 -39.60 -39.40 -113.40 -24.33 -25.63
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.77 0.74 0.71 0.68 0.64 0.62 0.58 0.57 0.54 0.52
Accounts Receivable Turnover
7.11 6.84 6.99 6.53 6.98 6.76 6.31 6.29 7.03 6.76
Inventory Turnover
10.19 9.91 10.21 10.41 11.22 10.22 11.68 11.40 11.41 10.15
Fixed Asset Turnover
7.09 6.98 7.03 7.21 7.44 7.80 8.48 9.78 10.69 11.93
Accounts Payable Turnover
8.68 8.00 6.79 6.94 8.65 7.20 7.20 6.70 6.92 8.56
Days Sales Outstanding (DSO)
51.31 53.38 52.21 55.91 52.31 54.02 57.84 58.00 51.89 54.03
Days Inventory Outstanding (DIO)
35.82 36.84 35.74 35.05 32.53 35.70 31.26 32.01 31.98 35.95
Days Payable Outstanding (DPO)
42.04 45.61 53.75 52.57 42.19 50.72 50.72 54.44 52.76 42.64
Cash Conversion Cycle (CCC)
45.09 44.62 34.20 38.39 42.65 39.01 38.38 35.58 31.11 47.34
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
638 671 676 694 681 636 646 726 716 657
Invested Capital Turnover
1.27 1.26 1.21 1.09 1.08 1.14 1.07 1.04 1.06 1.09
Increase / (Decrease) in Invested Capital
-43 35 30 -32 -35 -22 -18 115 146 103
Enterprise Value (EV)
1,185 2,427 2,155 1,687 1,471 1,266 1,801 1,778 1,006 1,279
Market Capitalization
1,248 2,488 2,214 1,752 1,573 1,313 1,890 1,887 1,176 1,539
Book Value per Share
$7.70 $8.06 $8.18 $8.45 $9.53 $8.35 $9.01 $10.28 $10.93 $11.37
Tangible Book Value per Share
$1.67 $1.46 $1.49 $1.47 $1.78 $0.49 $1.09 $2.20 $2.71 $3.84
Total Capital
741 771 779 799 822 722 774 835 886 917
Total Debt
40 39 39 39 39 39 38 0.00 0.00 0.00
Total Long-Term Debt
40 39 39 39 39 39 38 0.00 0.00 0.00
Net Debt
-63 -61 -59 -66 -102 -48 -89 -109 -170 -259
Capital Expenditures (CapEx)
5.90 6.30 8.90 8.60 14 18 19 24 15 18
Debt-free, Cash-free Net Working Capital (DFCFNWC)
32 39 45 40 17 -30 -48 40 23 30
Debt-free Net Working Capital (DFNWC)
134 139 143 144 158 56 73 118 137 223
Net Working Capital (NWC)
134 139 143 144 158 56 73 118 137 223
Net Nonoperating Expense (NNE)
15 8.10 11 6.47 9.22 19 37 18 5.76 3.60
Net Nonoperating Obligations (NNO)
-63 -61 -65 -66 -102 -48 -89 -109 -170 -259
Total Depreciation and Amortization (D&A)
15 16 15 16 15 14 13 19 14 13
Debt-free, Cash-free Net Working Capital to Revenue
3.76% 4.74% 5.66% 5.15% 2.23% -4.11% -6.93% 5.70% 3.32% 4.54%
Debt-free Net Working Capital to Revenue
15.99% 16.87% 17.79% 18.63% 20.94% 7.64% 10.47% 17.03% 20.25% 33.75%
Net Working Capital to Revenue
15.99% 16.87% 17.79% 18.63% 20.94% 7.64% 10.47% 17.03% 20.25% 33.75%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.47) ($0.24) ($0.41) ($0.29) ($0.34) ($0.75) ($1.42) ($0.67) ($0.52) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding
90.60M 90.90M 90.60M 89.90M 82.80M 81.90M 81.70M 81.30M 80.60M 80.70M
Adjusted Diluted Earnings per Share
($0.47) ($0.24) ($0.41) ($0.29) ($0.34) ($0.75) ($1.42) ($0.67) ($0.52) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding
90.60M 90.90M 90.60M 89.90M 82.80M 81.90M 81.70M 81.30M 80.60M 80.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
91.31M 91.04M 90.82M 90.51M 89.87M 82.20M 81.88M 81.56M 81.22M 81.03M
Normalized Net Operating Profit after Tax (NOPAT)
-27 -12 -17 -20 -22 -18 -25 -37 -32 -32
Normalized NOPAT Margin
-13.00% -5.84% -8.24% -9.66% -11.18% -9.41% -13.81% -20.17% -18.11% -20.14%
Pre Tax Income Margin
-18.61% -9.94% -17.59% -12.81% -16.43% -31.89% -63.27% -29.03% -29.30% -28.26%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-55.43 -26.00 -46.00 -52.00 -35.67 -60.80 -232.20 -105.60 -58.00 -55.63
NOPAT to Interest Expense
-39.10 -17.50 -31.94 -39.06 -24.42 -42.07 -159.18 -73.08 -40.60 -39.38
EBIT Less CapEx to Interest Expense
-63.86 -33.88 -57.13 -69.20 -50.67 -78.30 -269.80 -152.60 -74.22 -77.75
NOPAT Less CapEx to Interest Expense
-47.53 -25.38 -43.06 -56.26 -39.42 -59.57 -196.78 -120.08 -56.82 -61.50
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Myriad Genetics' Financials

When does Myriad Genetics's fiscal year end?

According to the most recent income statement we have on file, Myriad Genetics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Myriad Genetics' net income changed over the last 2 years?

Myriad Genetics' net income appears to be on an upward trend, with a most recent value of -$127.30 million in 2024, rising from -$112 million in 2022. The previous period was -$263.30 million in 2023. View Myriad Genetics' forecast to see where analysts expect Myriad Genetics to go next.

What is Myriad Genetics's operating income?
Myriad Genetics's total operating income in 2024 was -$123.50 million, based on the following breakdown:
  • Total Gross Profit: $585.40 million
  • Total Operating Expenses: $708.90 million
How has Myriad Genetics revenue changed over the last 2 years?

Over the last 2 years, Myriad Genetics' total revenue changed from $678.40 million in 2022 to $837.60 million in 2024, a change of 23.5%.

How much debt does Myriad Genetics have?

Myriad Genetics' total liabilities were at $326.50 million at the end of 2024, a 10.1% decrease from 2023, and a 4.3% increase since 2022.

How much cash does Myriad Genetics have?

In the past 2 years, Myriad Genetics' cash and equivalents has ranged from $56.90 million in 2022 to $132.10 million in 2023, and is currently $102.40 million as of their latest financial filing in 2024.

How has Myriad Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Myriad Genetics' book value per share changed from 10.93 in 2022 to 7.70 in 2024, a change of -29.5%.



This page (NASDAQ:MYGN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners